MedTrace Logo

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

NCT05518110 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-13

No results posted yet for this study

Summary

This study is designed to investigate the means by which cancer resists treatment can be overcome by a combination of an established anticancer drug, trametinib, with hydroxychloroquine.

Conditions

Interventions

DRUG

Trametinib

2mg of Trametinib (orally) daily.

DRUG

Hydroxychloroquine

1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Cancer Trials Ireland

    lead NETWORK

Principal Investigators

  • Austin Duffy · Mater Misericordiae University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2026-03-03
Completion
2026-03-03

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05518110 on ClinicalTrials.gov